Indeed, prospective randomized controlled trials showed that complete normalization of Hb from 126 to 135 g/dL has adverse effects on mortality and morbidity parameters such as blood pressure control in chronic kidney disease stages 3 and 4 [18,19], and on arterio-venous access thrombosis and mortality in dialysis patients [20]. Here, GSTM1 is linked to chronic kidney disease.